Vincenzi M, Morlino T, Allegri P, Barbieri E, Cappelletti F, De Lio U, Ometto R, Maiolino P
Clin Cardiol. 1981 Jan;4(1):15-21. doi: 10.1002/clc.4960040105.
Alterations in cardiovascular function induced by the acute intravenous administration of verapamil (5 or 10 mg) in 52 patients (29 with ischemic heart disease and 23 without heart disease) were evaluated with use of invasive techniques (right and left heart catheterization, left ventricular cineangiography, and coronary arteriography). The most significant changes were represented by a decrease in systemic vascular resistance and systemic arterial pressure, and an increase in heart rate and cardiac output. Contractility indexes were not depressed in either group, and altered ventricular wall motion tended to improve to a slightly smaller degree than in patients treated with nitroglycerin. The use of verapamil in patients with ischemic heart disease appears to be safe, and concern about the negative inotropic influences in humans no longer seems justified.
采用侵入性技术（右心和左心导管检查、左心室血管造影和冠状动脉造影）评估了52例患者（29例患有缺血性心脏病，23例无心脏病）急性静脉注射维拉帕米（5或10毫克）后心血管功能的变化。最显著的变化表现为全身血管阻力和体动脉压降低，心率和心输出量增加。两组的收缩性指标均未降低，与硝酸甘油治疗的患者相比，心室壁运动改变的改善程度略小。在缺血性心脏病患者中使用维拉帕米似乎是安全的，对人体负性肌力影响的担忧似乎不再合理。
